Core Insights - NewcelX Ltd. has announced the appointment of Professor Tamir Ben-Hur to its Scientific Advisory Board, enhancing its expertise in neuroimmunology and regenerative medicine [1][2][3] - The company aims to combine cell therapy with central nervous system drug innovation to advance treatments for neurodegenerative diseases such as ALS and Type 1 Diabetes [3][4] Company Overview - NewcelX Ltd. is a biotechnology company focused on developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases [4] - The company is headquartered in Zurich, Switzerland, with research and development operations in Ness Ziona, Israel [4] Strategic Developments - The merger between Kadimastem Ltd. and NLS Pharmaceutics Ltd. is expected to strengthen NewcelX's scientific foundation and enhance its capabilities in delivering breakthrough therapies [3] - Professor Ben-Hur's involvement is seen as a strong endorsement of the company's mission and scientific approach [3]